Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil 23 mg vs 10 mg in Japanese patients with severe Alzheimer's disease
jRCT2080221731Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of donepezil in Alzheimer's disease (AD) (2 arms), sponsored by Eisai Co., Ltd.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080221731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221731.